Jan Alenfall, CEO

Jan Alenfall holds a PhD and has over 20 years’ experience from pharmaceutical research and development, for example from research regarding new treatment for immunological diseases and cancer. Alenfall was Head of Pre-clinical and Clinical Development at Bioglan. He has also been Head of Research at Probi AB. Alenfall has solid experience within research, product development, pre-clinical and clinical trials and also in commercial collaborations. In 2006 he was appointed CEO at DermaGen AB. Alenfall has been the author and co-author of 17 publications in scientific journals and has six patent applications.


Shares in the company:
Alenfall owns 100 % of Callipa AB, which owns 293 180 shares in Follicum AB. Alenfall owns a further 22 726 warrants and 400 000 equity options in Follicum.

Maria Ekblad, R & D Director

Maria Ekblad has a Masters in Chemistry and more than 20 years’ experience in the pharmaceutical industry. Among these are research and development of new drugs for auto-immune diseases and cancer. In several assignments Maria was in charge of pre-clinical development at Active Biotech as well as their contract research services.

Maria Ekblad, R&D Director Follicum

Shares in the company:
Ekblad owns 8 332 shares in Follicum AB. Ekblad owns a further 1 666 warrants and 80 000 equity options in Follicum.

Gunnar Gårdemyr, CBO

Gunnar Gårdemyr has a Bachelors in economy and more than 35 years’ experience in the pharmaceutical and biotech industries. His focus has been business development, strategy and marketing in companies like Astra, Ferring, Nycomed, Takeda, Acino and Targovax. Gårdemyr has been CEO for Targovax AS, in charge of M & A at Nycomed as well as head of global marketing for Ferring.


Shares in the company:
Gårdemyr owns 133 483 shares in Follicum AB. Gårdemyr owns a further 26 696 warrants and 160 000 equity options in Follicum.